BDBM305804 2-(1-Ethyl-3-(4-(6-(5-(hydroxymethyl)-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrazin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile::US10144738, Example 3::US10822341, Example 3::US11472809, Example 3

SMILES CCN1CC(CC#N)(C1)n1cc(cn1)-c1nc(cn2nccc12)-c1cc(CO)[nH]n1

InChI Key InChIKey=XNFKXDZAZBECJS-UHFFFAOYSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 305804   

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 64nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 2.29E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 487nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 64nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 2.29E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 487nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/30/2019
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 64nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 2.29E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 487nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/21/2021
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 64nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 2.29E+3nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 487nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Pfizer

US Patent
LigandPNGBDBM305804(US10144738, Example 3 | 2-(1-Ethyl-3-(4-(6-(5-(hyd...)
Affinity DataIC50: 1.00E+4nMAssay Description:Compounds were added to a 384-well plate. Reaction mixtures contained 10 mM HEPES, pH 7.4, 10 mM MgCl2, 0.01% BSA, 0.0005% Tween 20, 1 mM ATP and 1 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/24/2022
Entry Details
Go to US Patent